Search

Your search keyword '"Horstmanshof, Douglas A."' showing total 14 results
Start Over Author "Horstmanshof, Douglas A." Publication Year Range Last 3 years
14 results on '"Horstmanshof, Douglas A."'

1. Concurrent valvular procedures during left ventricular assist device implantation and outcomes: A comprehensive analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 trial portfolio

Author

John, Ranjit, Kanwar, Manreet K., Cleveland, Joseph C., Jr., Uriel, Nir, Naka, Yoshifumi, Salerno, Christopher, Horstmanshof, Douglas, Hall, Shelley A., Cowger, Jennifer A., Heatley, Gerald, Somo, Sami I., and Mehra, Mandeep R.

Published
2023
Full Text
View/download PDF

3. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

Author

Lindenfeld, JoAnn, Zile, Michael R, Desai, Akshay S, Bhatt, Kunjan, Ducharme, Anique, Horstmanshof, Douglas, Krim, Selim R, Maisel, Alan, Mehra, Mandeep R, Paul, Sara, Sears, Samuel F, Sauer, Andrew J, Smart, Frank, Zughaib, Marcel, Castaneda, Paige, Kelly, Jean, Johnson, Nessa, Sood, Poornima, Ginn, Greg, Henderson, John, Adamson, Philip B, and Costanzo, Maria Rosa

Published
2021
Full Text
View/download PDF

6. Outcomes in Smaller Body Size Adults After HeartMate 3 Left Ventricular Assist Device Implantation

Author

Molina, Ezequiel J., primary, Cowger, Jennifer, additional, Lee, Sangjin, additional, Horstmanshof, Douglas, additional, Cleveland, Joseph C., additional, Goldstein, Daniel J., additional, Mehra, Mandeep R., additional, Uriel, Nir, additional, Salerno, Christopher T., additional, Bourque, Kevin, additional, Chuang, Joyce, additional, and Naka, Yoshifumi, additional

Published
2022
Full Text
View/download PDF

8. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial

Author

Mehra, Mandeep R., primary, Goldstein, Daniel J., additional, Cleveland, Joseph C., additional, Cowger, Jennifer A., additional, Hall, Shelley, additional, Salerno, Christopher T., additional, Naka, Yoshifumi, additional, Horstmanshof, Douglas, additional, Chuang, Joyce, additional, Wang, AiJia, additional, and Uriel, Nir, additional

Published
2022
Full Text
View/download PDF

10. Concurrent valvular procedures during left ventricular assist device implantation and outcomes: A comprehensive analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 trial portfolio

Author

John, Ranjit, primary, Kanwar, Manreet K., additional, Cleveland, Joseph C., additional, Uriel, Nir, additional, Naka, Yoshifumi, additional, Salerno, Christopher, additional, Horstmanshof, Douglas, additional, Hall, Shelley A., additional, Cowger, Jennifer A., additional, Heatley, Gerald, additional, Somo, Sami I., additional, and Mehra, Mandeep R., additional

Published
2022
Full Text
View/download PDF

13. Caregiver Health‐Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL

Author

Gilotra, Nisha A., primary, Pamboukian, Salpy V., additional, Mountis, Maria, additional, Robinson, Shawn W., additional, Kittleson, Michelle, additional, Shah, Keyur B., additional, Forde‐McLean, Rhondalyn C., additional, Haas, Donald C., additional, Horstmanshof, Douglas A., additional, Jorde, Ulrich P., additional, Russell, Stuart D., additional, Taddei‐Peters, Wendy C., additional, Jeffries, Neal, additional, Khalatbari, Shokoufeh, additional, Spino, Catherine A., additional, Richards, Blair, additional, Yosef, Matheos, additional, Mann, Douglas L., additional, Stewart, Garrick C., additional, Aaronson, Keith D., additional, and Grady, Kathleen L., additional

Published
2021
Full Text
View/download PDF

14. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.

Author

Mehra, Mandeep R., Cleveland, Joseph C., Uriel, Nir, Cowger, Jennifer A., Hall, Shelley, Horstmanshof, Douglas, Naka, Yoshifumi, Salerno, Christopher T., Chuang, Joyce, Williams, Christopher, Goldstein, Daniel J., Cleveland, Joseph C Jr, MOMENTUM 3 Investigators, and  on behalf of the MOMENTUM 3 Investigators

Subjects
HEART assist devices, INTRA-aortic balloon counterpulsation, OVERALL survival, HEART failure, SURVIVAL rate, HEART failure treatment, RESEARCH, STROKE, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, TREATMENT effectiveness, COMPARATIVE studies, LONGITUDINAL method
Abstract

Aim: The MOMENTUM 3 pivotal trial established superiority of the HeartMate 3 (HM3) left ventricular assist device (LVAD), a fully magnetically levitated centrifugal-flow pump, over the HeartMate II axial-flow pump. We now evaluate HM3 LVAD outcomes in a single-arm prospective continuous access protocol (CAP) post-pivotal trial study.Methods and Results: We enrolled 2200 HM3 implanted patients (515 pivotal trial and 1685 CAP patients) and compared outcomes including survival free of disabling stroke or reoperation to replace or remove a malfunctioning device (primary composite endpoint), overall survival and major adverse events at 2 years. The 2-year primary endpoint [76.7% vs. 74.8%; adjusted hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.71-1.08, P = 0.21] and overall survival (81.2% vs. 79.0%) were similar among CAP and pivotal cohorts despite sicker patients (more intra-aortic balloon pump use and INTERMACS profile 1) in CAP who were more often intended for destination therapy. Survival was similar between the CAP and pivotal trial in transplant ineligible patients (79.1% vs. 76.7%; adjusted HR 0.89, 95% CI 0.68-1.16, P = 0.38). In a pooled analysis, the 2-year primary endpoint was similar between INTERMACS profiles 1-2 ('unstable' advanced heart failure), profile 3 ('stable' on inotropic therapy), and profiles 4-7 ('stable' ambulatory advanced heart failure) (75.7% vs. 77.6% vs. 72.9%, respectively). The net burden of adverse events was lower in CAP (adjusted rate ratio 0.93, 95% CI 0.88-0.98, P = 0.006), with consequent decrease in hospitalization.Conclusions: The primary results of accumulating HM3 LVAD experience suggest a lower adverse event burden and similar survival compared to the pivotal MOMENTUM 3 trial. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results